The impact of nonmotor symptoms on quality of life in patients with Parkinson's disease in Taiwan
Authors Liu W, Lin R, Yu R, Tai C, Lin C, Wu R
Received 21 May 2015
Accepted for publication 20 August 2015
Published 11 November 2015 Volume 2015:11 Pages 2865—2873
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Ryouhei Ishii
Peer reviewer comments 2
Editor who approved publication: Professor Wai Kwong Tang
Weng-Ming Liu,1,2 Ru-Jen Lin,1 Rwei-Ling Yu,3 Chun-Hwei Tai,1 Chin-Hsien Lin,1 Ruey-Meei Wu1
1Department of Neurology, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan; 2Department of Neurology, Buddhist Tzu Chi General Hospital, Hualien, Taiwan; 3Institute of Behavioral Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan
Purpose: The nonmotor symptoms (NMS) of Parkinson’s disease (PD) are important factors for quality of life (QoL). Few studies on NMS have been conducted in Asian PD patients. Additionally, effects of anti-PD drugs on risk of NMS are still controversial. We therefore conducted this hospital-based cross-sectional study to examine the clinical factors, including concomitant anti-PD medication use, on the occurrence of NMS and QoL in Taiwanese PD patients.
Patients and methods: PD patients who received long-term follow-up in the movement disorders clinics were enrolled and received NMS questionnaire (NMSQuest) and the 39-item Parkinson’s Disease Questionnaire (PDQ-39). Spearman’s rank correlation coefficient was checked for the correlation between clinical factors and NMSQT/PDQSI. Multiple linear regressions were applied to assess the influence of clinical factors on NMSQT/PDQSI.
Results: A total of 210 PD patients (mean age 66.1±9.86 years, Hoehn and Yahr stage 2.2±0.9) were included in this study. Up to 98% of patients reported at least one symptom of NMS. The most prevalent symptom was urinary complaints (56%), followed by memory/apathy (30%) and depression/anxiety (28%). The correlation between NMSQT and PDQSI was strong (rs=0.667), especially the item of depression/anxiety (rs=0.607). The regression model for NMSQT indicated that disease duration and severity, but not pharmacological therapy, were major predictors of NMS.
Conclusion: Our data indicated a high prevalence rate of NMS in PD patients. Among symptoms of NMS, depression and anxiety had the greatest impact on QoL. Concomitant anti-PD medication use did not affect the occurrence of NMS and QoL.
Keywords: NMS, NMSQuest, NMS questionnaire, PD, PDQ-39, PDQSI
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]